Clinical Trial

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-31.
Status change: Active, Not Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT06446128
Lead Sponsor Shanghai Cell Therapy Group Co.,Ltd
Conditions Non-Hodgkin Lymphoma, B-cell
Enrollment 20 participants
Start Date 2024-05-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-21